| . | Participants, No. (%)a . | |||
|---|---|---|---|---|
| . | . | A5336 . | . | |
| Characteristic . | Total (N = 44) . | Ruxolitinib (n = 26) . | No Treatment (n = 10) . | A5337 (n = 8) . |
| Age, y | ||||
| Median (IQR) | 49 (43–55) | 49.5 (46–55) | 43 (33–49) | 51 (46–545) |
| Range | 25–62 | 29–62 | 25–58 | 27–62 |
| Sex | ||||
| Male | 34 (77) | 21 (81) | 7 (70) | 6 (75) |
| Female | 10 (23) | 5 (19) | 3 (30) | 2 (25) |
| Race/ethnicity | ||||
| White non-Hispanic | 16 (37) | 9 (36) | 3 (30) | 4 (50) |
| Black non-Hispanic | 20 (47) | 12 (48) | 5 (50) | 3 (38) |
| Hispanic (any race) | 5 (12) | 3 (12) | 1 (10) | 1 (13) |
| >1 Race | 2 (5) | 1 (4) | 1 (10) | 0 (0) |
| History of intravenous drug use | ||||
| Never | 36 (82) | 20 (77) | 9 (90) | 7 (88) |
| Previously | 8 (18) | 6 (23) | 1 (10) | 1 (13) |
| BMIb | ||||
| Normal (18.5 to <25) | 10 (23) | 6 (23) | 1 (10) | 3 (38) |
| Overweight (25 to <30) | 14 (32) | 8 (31) | 4 (40) | 2 (25) |
| Obese (≥30) | 20 (45) | 12 (46) | 5 (50) | 3 (38) |
| Baseline CD4+/CD+8 T-cell ratio | ||||
| <0.5 | 1 (2) | 1 (4) | 0 (0) | 0 (0) |
| 0.5–1 | 16 (36) | 9 (35) | 3 (30) | 4 (50) |
| >1 | 27 (61) | 16 (62) | 7 (70) | 4 (50) |
| ART regimen | ||||
| EFV/FTC/TDF | 14 (32) | 7 (27) | 3 (30) | 4 (50) |
| ABC/DTG/3TC | 7 (16) | 6 (23) | 0 (0) | 1 (13) |
| FTC/RPV/TAF | 6 (14) | 3 (12) | 3 (30) | 0 (0) |
| RAL and FTC/TAF | 4 (9) | 2 (8) | 2 (20) | 0 (0) |
| TRV and RAL | 4 (9) | 3 (12) | 1 (10) | 0 (0) |
| DTG and FTC/TAF | 3 (7) | 2 (8) | 1 (10) | 0 (0) |
| Other | 6 (14) | 3 (12) | 0 (0) | 3 (38) |
| Entry CMV levels | ||||
| Genital secretion sample | ||||
| Median (IQR), copies/mL | 0 (0–38) | 0 (0–2604) | 0 (0–38) | 0 (0–0) |
| Undetectable | 27 (73) | 15 (71) | 6 (67) | 6 (86) |
| Detectable | 10 (27) | 6 (29) | 3 (33) | 1 (14) |
| Oral swab sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 41 (93) | 23 (88) | 10 (100) | 8 (100) |
| Detectable | 3 (7) | 3 (12) | 0 (0) | 0 (0) |
| Urine sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 38 (86) | 22 (85) | 8 (80) | 8 (100) |
| Detectable | 6 (14) | 4 (15) | 2 (20) | 0 (0) |
| Entry CMV IgG level | ||||
| Median (IQR), IU/mL | 31.7 (21.2–41.0) | 34.4 (25.8–41.5) | 22.1 (18.6–39.3) | 31.3 (24.9–41.1) |
| Undetectable | 5 (11) | 3 (12) | 1 (10) | 1 (13) |
| Detectable | 39 (89) | 23 (88) | 9 (90) | 7 (88) |
| . | Participants, No. (%)a . | |||
|---|---|---|---|---|
| . | . | A5336 . | . | |
| Characteristic . | Total (N = 44) . | Ruxolitinib (n = 26) . | No Treatment (n = 10) . | A5337 (n = 8) . |
| Age, y | ||||
| Median (IQR) | 49 (43–55) | 49.5 (46–55) | 43 (33–49) | 51 (46–545) |
| Range | 25–62 | 29–62 | 25–58 | 27–62 |
| Sex | ||||
| Male | 34 (77) | 21 (81) | 7 (70) | 6 (75) |
| Female | 10 (23) | 5 (19) | 3 (30) | 2 (25) |
| Race/ethnicity | ||||
| White non-Hispanic | 16 (37) | 9 (36) | 3 (30) | 4 (50) |
| Black non-Hispanic | 20 (47) | 12 (48) | 5 (50) | 3 (38) |
| Hispanic (any race) | 5 (12) | 3 (12) | 1 (10) | 1 (13) |
| >1 Race | 2 (5) | 1 (4) | 1 (10) | 0 (0) |
| History of intravenous drug use | ||||
| Never | 36 (82) | 20 (77) | 9 (90) | 7 (88) |
| Previously | 8 (18) | 6 (23) | 1 (10) | 1 (13) |
| BMIb | ||||
| Normal (18.5 to <25) | 10 (23) | 6 (23) | 1 (10) | 3 (38) |
| Overweight (25 to <30) | 14 (32) | 8 (31) | 4 (40) | 2 (25) |
| Obese (≥30) | 20 (45) | 12 (46) | 5 (50) | 3 (38) |
| Baseline CD4+/CD+8 T-cell ratio | ||||
| <0.5 | 1 (2) | 1 (4) | 0 (0) | 0 (0) |
| 0.5–1 | 16 (36) | 9 (35) | 3 (30) | 4 (50) |
| >1 | 27 (61) | 16 (62) | 7 (70) | 4 (50) |
| ART regimen | ||||
| EFV/FTC/TDF | 14 (32) | 7 (27) | 3 (30) | 4 (50) |
| ABC/DTG/3TC | 7 (16) | 6 (23) | 0 (0) | 1 (13) |
| FTC/RPV/TAF | 6 (14) | 3 (12) | 3 (30) | 0 (0) |
| RAL and FTC/TAF | 4 (9) | 2 (8) | 2 (20) | 0 (0) |
| TRV and RAL | 4 (9) | 3 (12) | 1 (10) | 0 (0) |
| DTG and FTC/TAF | 3 (7) | 2 (8) | 1 (10) | 0 (0) |
| Other | 6 (14) | 3 (12) | 0 (0) | 3 (38) |
| Entry CMV levels | ||||
| Genital secretion sample | ||||
| Median (IQR), copies/mL | 0 (0–38) | 0 (0–2604) | 0 (0–38) | 0 (0–0) |
| Undetectable | 27 (73) | 15 (71) | 6 (67) | 6 (86) |
| Detectable | 10 (27) | 6 (29) | 3 (33) | 1 (14) |
| Oral swab sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 41 (93) | 23 (88) | 10 (100) | 8 (100) |
| Detectable | 3 (7) | 3 (12) | 0 (0) | 0 (0) |
| Urine sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 38 (86) | 22 (85) | 8 (80) | 8 (100) |
| Detectable | 6 (14) | 4 (15) | 2 (20) | 0 (0) |
| Entry CMV IgG level | ||||
| Median (IQR), IU/mL | 31.7 (21.2–41.0) | 34.4 (25.8–41.5) | 22.1 (18.6–39.3) | 31.3 (24.9–41.1) |
| Undetectable | 5 (11) | 3 (12) | 1 (10) | 1 (13) |
| Detectable | 39 (89) | 23 (88) | 9 (90) | 7 (88) |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BMI, body mass index; CMV, cytomegalovirus; DTG, dolutegravir; FTC, emtricitabine; IgG, immunoglobulin G; IQR, interquartile range; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir; TRV, truvada (Emtricitabine/Tenofovir).
Data represent no. (%) of participants unless otherwise specified.
BMI calculated as weight in kilograms divided by height in meters squared.
| . | Participants, No. (%)a . | |||
|---|---|---|---|---|
| . | . | A5336 . | . | |
| Characteristic . | Total (N = 44) . | Ruxolitinib (n = 26) . | No Treatment (n = 10) . | A5337 (n = 8) . |
| Age, y | ||||
| Median (IQR) | 49 (43–55) | 49.5 (46–55) | 43 (33–49) | 51 (46–545) |
| Range | 25–62 | 29–62 | 25–58 | 27–62 |
| Sex | ||||
| Male | 34 (77) | 21 (81) | 7 (70) | 6 (75) |
| Female | 10 (23) | 5 (19) | 3 (30) | 2 (25) |
| Race/ethnicity | ||||
| White non-Hispanic | 16 (37) | 9 (36) | 3 (30) | 4 (50) |
| Black non-Hispanic | 20 (47) | 12 (48) | 5 (50) | 3 (38) |
| Hispanic (any race) | 5 (12) | 3 (12) | 1 (10) | 1 (13) |
| >1 Race | 2 (5) | 1 (4) | 1 (10) | 0 (0) |
| History of intravenous drug use | ||||
| Never | 36 (82) | 20 (77) | 9 (90) | 7 (88) |
| Previously | 8 (18) | 6 (23) | 1 (10) | 1 (13) |
| BMIb | ||||
| Normal (18.5 to <25) | 10 (23) | 6 (23) | 1 (10) | 3 (38) |
| Overweight (25 to <30) | 14 (32) | 8 (31) | 4 (40) | 2 (25) |
| Obese (≥30) | 20 (45) | 12 (46) | 5 (50) | 3 (38) |
| Baseline CD4+/CD+8 T-cell ratio | ||||
| <0.5 | 1 (2) | 1 (4) | 0 (0) | 0 (0) |
| 0.5–1 | 16 (36) | 9 (35) | 3 (30) | 4 (50) |
| >1 | 27 (61) | 16 (62) | 7 (70) | 4 (50) |
| ART regimen | ||||
| EFV/FTC/TDF | 14 (32) | 7 (27) | 3 (30) | 4 (50) |
| ABC/DTG/3TC | 7 (16) | 6 (23) | 0 (0) | 1 (13) |
| FTC/RPV/TAF | 6 (14) | 3 (12) | 3 (30) | 0 (0) |
| RAL and FTC/TAF | 4 (9) | 2 (8) | 2 (20) | 0 (0) |
| TRV and RAL | 4 (9) | 3 (12) | 1 (10) | 0 (0) |
| DTG and FTC/TAF | 3 (7) | 2 (8) | 1 (10) | 0 (0) |
| Other | 6 (14) | 3 (12) | 0 (0) | 3 (38) |
| Entry CMV levels | ||||
| Genital secretion sample | ||||
| Median (IQR), copies/mL | 0 (0–38) | 0 (0–2604) | 0 (0–38) | 0 (0–0) |
| Undetectable | 27 (73) | 15 (71) | 6 (67) | 6 (86) |
| Detectable | 10 (27) | 6 (29) | 3 (33) | 1 (14) |
| Oral swab sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 41 (93) | 23 (88) | 10 (100) | 8 (100) |
| Detectable | 3 (7) | 3 (12) | 0 (0) | 0 (0) |
| Urine sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 38 (86) | 22 (85) | 8 (80) | 8 (100) |
| Detectable | 6 (14) | 4 (15) | 2 (20) | 0 (0) |
| Entry CMV IgG level | ||||
| Median (IQR), IU/mL | 31.7 (21.2–41.0) | 34.4 (25.8–41.5) | 22.1 (18.6–39.3) | 31.3 (24.9–41.1) |
| Undetectable | 5 (11) | 3 (12) | 1 (10) | 1 (13) |
| Detectable | 39 (89) | 23 (88) | 9 (90) | 7 (88) |
| . | Participants, No. (%)a . | |||
|---|---|---|---|---|
| . | . | A5336 . | . | |
| Characteristic . | Total (N = 44) . | Ruxolitinib (n = 26) . | No Treatment (n = 10) . | A5337 (n = 8) . |
| Age, y | ||||
| Median (IQR) | 49 (43–55) | 49.5 (46–55) | 43 (33–49) | 51 (46–545) |
| Range | 25–62 | 29–62 | 25–58 | 27–62 |
| Sex | ||||
| Male | 34 (77) | 21 (81) | 7 (70) | 6 (75) |
| Female | 10 (23) | 5 (19) | 3 (30) | 2 (25) |
| Race/ethnicity | ||||
| White non-Hispanic | 16 (37) | 9 (36) | 3 (30) | 4 (50) |
| Black non-Hispanic | 20 (47) | 12 (48) | 5 (50) | 3 (38) |
| Hispanic (any race) | 5 (12) | 3 (12) | 1 (10) | 1 (13) |
| >1 Race | 2 (5) | 1 (4) | 1 (10) | 0 (0) |
| History of intravenous drug use | ||||
| Never | 36 (82) | 20 (77) | 9 (90) | 7 (88) |
| Previously | 8 (18) | 6 (23) | 1 (10) | 1 (13) |
| BMIb | ||||
| Normal (18.5 to <25) | 10 (23) | 6 (23) | 1 (10) | 3 (38) |
| Overweight (25 to <30) | 14 (32) | 8 (31) | 4 (40) | 2 (25) |
| Obese (≥30) | 20 (45) | 12 (46) | 5 (50) | 3 (38) |
| Baseline CD4+/CD+8 T-cell ratio | ||||
| <0.5 | 1 (2) | 1 (4) | 0 (0) | 0 (0) |
| 0.5–1 | 16 (36) | 9 (35) | 3 (30) | 4 (50) |
| >1 | 27 (61) | 16 (62) | 7 (70) | 4 (50) |
| ART regimen | ||||
| EFV/FTC/TDF | 14 (32) | 7 (27) | 3 (30) | 4 (50) |
| ABC/DTG/3TC | 7 (16) | 6 (23) | 0 (0) | 1 (13) |
| FTC/RPV/TAF | 6 (14) | 3 (12) | 3 (30) | 0 (0) |
| RAL and FTC/TAF | 4 (9) | 2 (8) | 2 (20) | 0 (0) |
| TRV and RAL | 4 (9) | 3 (12) | 1 (10) | 0 (0) |
| DTG and FTC/TAF | 3 (7) | 2 (8) | 1 (10) | 0 (0) |
| Other | 6 (14) | 3 (12) | 0 (0) | 3 (38) |
| Entry CMV levels | ||||
| Genital secretion sample | ||||
| Median (IQR), copies/mL | 0 (0–38) | 0 (0–2604) | 0 (0–38) | 0 (0–0) |
| Undetectable | 27 (73) | 15 (71) | 6 (67) | 6 (86) |
| Detectable | 10 (27) | 6 (29) | 3 (33) | 1 (14) |
| Oral swab sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 41 (93) | 23 (88) | 10 (100) | 8 (100) |
| Detectable | 3 (7) | 3 (12) | 0 (0) | 0 (0) |
| Urine sample | ||||
| Median (IQR), copies/mL | 0 (0-0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Undetectable | 38 (86) | 22 (85) | 8 (80) | 8 (100) |
| Detectable | 6 (14) | 4 (15) | 2 (20) | 0 (0) |
| Entry CMV IgG level | ||||
| Median (IQR), IU/mL | 31.7 (21.2–41.0) | 34.4 (25.8–41.5) | 22.1 (18.6–39.3) | 31.3 (24.9–41.1) |
| Undetectable | 5 (11) | 3 (12) | 1 (10) | 1 (13) |
| Detectable | 39 (89) | 23 (88) | 9 (90) | 7 (88) |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BMI, body mass index; CMV, cytomegalovirus; DTG, dolutegravir; FTC, emtricitabine; IgG, immunoglobulin G; IQR, interquartile range; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir; TRV, truvada (Emtricitabine/Tenofovir).
Data represent no. (%) of participants unless otherwise specified.
BMI calculated as weight in kilograms divided by height in meters squared.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
